Larimar Therapeutics
data is generally well tolerated | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
14 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
appeared to be generally well tolerated in phase trial cohort | Larimar Therapeutics
Investor Presentation
November 2023
repeated subcutaneous injections of were generally well tolerated in phase mad trial | Larimar Therapeutics
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
April 2023
interim results from phase clinical trial safety summary | Aeglea BioTherapeutics
NeuroSense Therapeutics
Investor Presentation
January 2024
achieved primary with a safety and tolerability profile comparable to placebo phase study results | NeuroSense Therapeutics
Anebulo Pharmaceuticals
Investor Day
September 2022
clinical trial design part a challenge study | Anebulo Pharmaceuticals
Avenue Therapeutics
IPO
October 2022
completed clinical studies and demonstrated safety across trials | Avenue Therapeutics
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights